Search MU Research.

MU Home / Provost / MU Research / Funding / OGWP / Limited Submission Announcements / NIH IPCAVD

Limited Submission Announcements

OGWP Calendar.
Research Calendar.

Last update


The NIH Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program supports the translation of meritorious HIV/AIDS prophylactic vaccine candidates from the bench to the clinic. As such, initiation of human studies during the term of funding must be a feasible and established goal. Consistent with these goals, the IPCAVD Program is designed to support more advanced later stages of vaccine research and development and applications must include Phase I human studies.

Projects responsive to this announcement include but are not limited to:

  • advanced stage preclinical research (such as vaccine optimization studies, immunogenicity/challenge studies in non-human primates, etc.);
  • GLP preclinical toxicology and safety studies;
  • GMP vaccine production;
  • Pre-IND/IND preparation and submission; and
  • clinical testing.

Because MU is limited to one application for this program, letters of intent must be submitted to the Office of Research,, no later than 5:00 pm Friday, May 12, 2006. Letters of intent should be limited to three pages and should include a summary of the proposed project.


Approximately $2 million annual direct costs for up to 5 years

MU Deadline: 5:00 p.m., Friday, May 12, 2006 (letter of intent)
Sponsor Deadline:

July 24, 2006

URL for more information:

This notice is being sent to deans, directors, and chairs in life science disciplines. Please forward it to other faculty members who may be interested.

All limited submission announcements can be tracked by deadline via the Calendar at or by announcement date via the Limited Submissions listing at

University of Missouri Columbia: Office of Research. Site map.